Drug Profile
TNF 484
Latest Information Update: 06 Oct 2006
Price :
$50
*
At a glance
- Originator Novartis
- Class
- Mechanism of Action Metalloprotease inhibitors; Tumour necrosis factor-alpha convertase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial meningitis
Most Recent Events
- 06 Oct 2006 Discontinued - Preclinical for Bacterial meningitis in Switzerland (unspecified route)
- 27 Sep 2000 Preclinical development for Bacterial meningitis in Switzerland (Unknown route)